Robert Bradway News Today

Welcome everybody to todays hybrid hearing. Pursuant to house rules, some members will appear in person and others will appear remotely via webx. Some members are appearing in person. Let me first remind everyone that pursuant to the latest guidance from the attending physician, all individuals attending the hearing in person must wear a face mask unless you are speaking. Members not wearing a face mask will not be recognized. Let me also make a few reminders for these members appearing in perso...

Hybrid hearing. Pursuant to house rules, some members will appear in person and others will appear remotely via webx. Some members are appearing in person. Let me first remind everyone that pursuant to the latest guidance from the attending physician, all individuals attending the hearing in person must wear a face mask unless you are speaking. Members not wearing a face mask will not be recognized. Let me also make a few reminders for these members appearing in person. You will only see members...

Members will appear in person and others will appear remotely via webx. Some members are appearing in person. Let me first remind everyone that pursuant to the latest guidance from the attending physician, all individuals attending the hearing in person must wear a face mask unless you are speaking. Members not wearing a face mask will not be recognized. Let me also make a few reminders for these members appearing in person. You will only see members and witnesses appearing remotely on the monit...

Cspan. Org. We will show you as much it as we can right now. Thank you very much. Later on this morning congressman Brian Higgins from buffalo, new york, is going to be offering an amendment that i think is going to test the theory that has been put forward by the head of the president s counsel of economic advisers who has promised that if their tax proposal passes as is, which as you can see today based upon the commentary of the republican leadership, it is likely to be changed from the time ...

The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.

Goldman Sachs said Amgen's experimental GLP-1 drug could have peak sales of $5 billion, or 5% of the estimated $100 billion weight loss drug market.

MariTide, formerly AMG 133, is an injectable form of drug targeting two gut hormones — gastric inhibitory polypeptide receptor, or GIP, and glucagon-like peptide 1, or GLP-1.

Amgen earnings beat estimates, and MariTide's promising Phase 2 results suggest significant differentiation from competitors.

-U.S. drugmaker Amgens shares jumped 14% premarket on Friday as the company said it was encouraged by interim trial data on its experimental obesity drug, denting rival stocks but... -May 03, 2024 at 06:16 am EDT - MarketScreener

Amgen shares surged more than 14% in late trade Thursday after topping Q1 earnings estimates and providing a positive update on its injectable weigh-loss drug MariTide.